TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22733022
Drug: Hybrid flavopiridol
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid flavopiridol (30 mg/m² over 30 min followed by 40 mg/m² over 4 h, Arm B)
Study: 17588490
Drug: 12-step-based drug
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-step-based drug treatment program (Treatment group)
Study: 16320747
Drug: Electroacupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture and ultrashort‐wave treatment from the acute stage (Group A)
Study: 16320747
Drug: Ultrashort‐wave treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrashort‐wave treatment at the acute stage and ultrashort‐wave plus electroacupuncture at the resting stage (Group B)
Study: 11782652
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (2.5 g x kg(‐1) x d(‐1) CHO, 4.3 g x kg(‐1) x d(‐1) fat; FAT-adapt)
Study: 11782652
Drug: High-carbohydrate diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate diet (9.3 g x kg(‐1) x d(‐1) CHO, 1.1 g x kg(‐1) x d(‐1) fat; HCHO)
Study: 7853690
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) at 20 mg/kg
Study: 7853690
Drug: Cefozopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefozopran (CZOP) at 40 mg/kg
Study: 66871
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B immune serum globulin (antibody titer 1:355,000)
Study: 6101354
Drug: Post-treatment equilin
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment equilin levels in group 1
Study: 6101354
Drug: Post-treatment equilin
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment equilin levels in group 2
Study: 30964969
Drug: Oral‐B Genius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Genius 8000 with FlossAction brush head (OBG)
Study: 30964969
Drug: Oral‐B Genius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B Genius 8000 (OBG)
Study: 27129571
Drug: Preoperative ultrasound-guided
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative ultrasound-guided bilateral TAP block with 0.5 mL/kg of 0.25% bupivacaine
Study: 27345639
Drug: Deferred radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred radiotherapy (same dose given within 35 days of PTM diagnosis)
Study: 11222470
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg TID (n=20)
Study: 9893547
Drug: Pethidine 5
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 5 mg.ml‐1 with adrenaline 5 micrograms.ml‐1 (adrenaline group)
Study: 9893547
Drug: Pethidine 5
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 5 mg.ml‐1 without adrenaline (plain group)
Study: 7986965
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg b.d. for 6 days
Study: 2735519
Drug: Turbuhaler (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turbuhaler (0.5 mg terbutaline sulphate)
Study: 2735519
Drug: Metered Dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered Dose Inhaler (MDI) (0.5 mg terbutaline sulphate)
Study: 31200823
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (icotinib plus pemetrexed and carboplatin)
Study: 27865015
Drug: Any cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any cannabis use during treatment
Study: 23644079
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg ∙ kg(‐1) ∙ day(‐1))
Study: 23644079
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management (immunosuppressant therapy only if corticosteroid dependency, chronic active disease, poor response to corticosteroids, or severe perianal disease)
Study: 21078826
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered every 2 weeks for 2 months on and 2 months off (arm A)
Study: 21078826
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy with levo‐leucovorin + 5‐fluorouracil (5‐FU) + irinotecan (CPT‐11), administered continuously (arm B)
Study: 21078826
Drug: Intermittent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent chemotherapy (arm A)
Study: 21078826
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (arm B)
Study: 21078826
Drug: Second-line oxaliplatin-based
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second-line oxaliplatin-based treatment
Study: 15001789
Drug: Daily additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily additional sensorimotor stimulation of the arm for 6 weeks
Study: 10744088
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alosetron orally twice daily for 12 weeks
Study: 10744088
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily for 12 weeks
Study: 8759064
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg daily)
Study: 30995176
Drug: Idelalisib (IDELA)
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib (IDELA) 150 mg twice daily plus rituximab
Study: 27889290
Drug: Topical broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical broccoli sprout extract (BSE) (500 nmol of sulforaphane/mL)
Study: 17638004
Drug: Patching plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching plus oral CDP‐choline (800 or 1,200 mg based on body weight) for 30 days
Study: 7574020
Drug: 6% hetastarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hetastarch plus 1 L lactated Ringer's solution (n = 20)
Study: 7574020
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (n = 20)
Study: 1662879
Drug: Oral temafloxacin
Normalized name: TEMAFLOXACIN
DrugBank: Temafloxacin (DB01405)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral temafloxacin (600 mg b.i.d.)
Study: 1662879
Drug: Oral cefadroxil
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cefadroxil (500 mg b.i.d.)
Study: 31706460
Drug: Abriendo Caminos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abriendo Caminos Program (6 weekly, 2-hour group workshops on nutrition education, family wellness, and physical activity)
Study: 22688849
Drug: Peginterferon/ribavirin lead-in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon/ribavirin lead-in therapy
Study: 19223704
Drug: Active surgical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active surgical treatment
Study: 15902303
Drug: Mutated nonautoreactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutated nonautoreactive CLL antibody sequences reverted to germline counterparts
Study: 12581508
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium aerosol (4 mg) inhaled 30 minutes before allergen challenge
Study: 9873197
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of GH
Study: 9873197
Drug: Combined continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined continuous infusion and bolus injections of GH
Study: 9873197
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections of GH
Study: 9873197
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous (s.c.) infusion of GH
Study: 9873197
Drug: Daily s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily s.c. injections of GH
Study: 6356898
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg (single dose and three times a day for three days)
Study: 6356898
Drug: Labetalol 300
Normalized name: labetalol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 300 mg (single dose and twice a day for three days)
Study: 6356898
Drug: Labetalol 200
Normalized name: HCTZ 25/LABETALOL 200MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 200 mg three times a day
Study: 6356898
Drug: Labetalol 300
Normalized name: labetalol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol 300 mg twice a day
Study: 29608340
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (4 weekly 1-hour group-based exercise classes targeting strength training, endurance, balance, and flexibility)
Study: 30205379
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day plus PTX (400 mg b.i.d.)
Study: 30205379
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day plus placebo
Study: 25823668
Drug: RG7652 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 400 mg every 4 weeks
Study: 25823668
Drug: RG7652 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7652 800 mg every 8 weeks
Study: 8669268
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg a day
Study: 8669268
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg a day (combined with Cetirizine)
Study: 9338613
Drug: Azelastine (Allergodil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (Allergodil nasal spray)
Study: 6395279
Drug: Multiple-dose cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose cefoxitin
Study: 6395279
Drug: Single-dose cefonicid
Normalized name: cefonicid
DrugBank: Cefonicid (DB01328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefonicid
Study: 29577681
Drug: Radotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radotinib (400 mg once daily)
Study: 24475284
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no endotoxin administration)
Study: 22776778
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg saxagliptin QD + COC QD for 21 days
Study: 22776778
Drug: COC (Ortho-Cyclen)
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COC (Ortho-Cyclen) once daily for 21 days
Study: 21135325
Drug: Maintenance antidepressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressant medication
Study: 9861123
Drug: Morphine 0.3
Normalized name: ethylmorphine 0.32 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.3 mg kg-1 at induction of anaesthesia
Study: 9861123
Drug: Placebo (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (morphine given 30 min later at skin incision)
Study: 2664670
Drug: Intraoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative and postoperative cefuroxime (1500 mg and 750 mg intravenously, followed by 750 mg every eight hours for 24 hours postoperatively)
Study: 2664670
Drug: Intraoperative cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative cefuroxime (1500 mg and 750 mg intravenously)
Study: 1276626
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy followed by chemotherapy
Study: 31170077
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of wrist robot-assisted training and tDCS
Study: 28500815
Drug: Oral pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentoxifylline plus pentavalent antimony (Sbv)
Study: 20740685
Drug: Odanacatib (ODN)
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (ODN) 50 mg weekly
Study: 2446060
Drug: Ketanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20 mg) + Hydrochlorothiazide (25 mg)
Study: 2446060
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg) + Hydrochlorothiazide (12.5 mg)
Study: 27110370
Drug: Sitagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (50 mg, once daily)
Study: 27110370
Drug: Voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.6 mg, thrice daily)
Study: 20633748
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon treatment (IFA) for 24 weeks
Study: 18691996
Drug: Rosuvastatin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin vs Pravastatin 20 mg
Study: 12464950
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg/daily for 3 weeks
Study: 12464950
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg/daily for 6 weeks
Study: 12464950
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg/daily
Study: 7573091
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 40 mg methylprednisolone acetate
Study: 7573091
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 40 mg methylprednisolone acetate
Study: 28369340
Drug: Vericiguat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (10 mg)
Study: 28369340
Drug: Vericiguat (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (pooled three highest dose arms)
Study: 25648342
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and daily tadalafil (5 mg) for 30 weeks
Study: 25648342
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with injectable testosterone undecanoate (1,000 mg on day 1, additional injections at weeks 6 and 18) and on-demand tadalafil (10-20 mg) for 30 weeks
Study: 25648342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same testosterone treatment but with on-demand tadalafil (10-20 mg)
Study: 25648342
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (daily tadalafil 5 mg)
Study: 21198671
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated vaccines
Study: 21198671
Drug: Inactivated vaccines
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccines
Study: 21198671
Drug: Inactivated vaccines
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccines with oil-in-water emulsion adjuvants (e.g., MF59)
Study: 21198671
Drug: Non-adjuvanted inactivated
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted inactivated vaccines
Study: 12937039
Drug: Serum CMV
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CMV IgM antibodies
Study: 11106042
Drug: Ceftriaxone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (50 mg/kg)
Study: 3545882
Drug: Biostim 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim 2 mg/day
Study: 3545882
Drug: Biostim 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim 8 mg/day
Study: 31503274
Drug: Methotrexate (25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (25mg weekly)
Study: 31503274
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (3g daily)
Study: 24383914
Drug: Vi vaccine
Normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi vaccine (Typherix(®))
Study: 24383914
Drug: Ty21a vaccine
Normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a vaccine (Vivotif(®))
Study: 15849398
Drug: Antibiotics (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (group A)
Study: 15849398
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (group B)
Study: 9257789
Drug: D5159 (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5159 (8 mg)
Study: 8421248
Drug: Caffeine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 3.0 mg/kg
Study: 8421248
Drug: Placebo (0.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0 mg/kg caffeine)
Study: 31327292
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly group-exercises and physical activity counselling
Study: 29421002
Drug: Edoxaban-based strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban-based strategy (60 mg or 30 mg once daily) plus P2Y12 antagonist (clopidogrel, 75 mg once daily) for 12 months
Study: 29421002
Drug: VKA-based strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA-based strategy (VKA plus P2Y12 antagonist and acetylsalicylic acid 100 mg once daily) for 30 days to 12 months
Study: 27480131
Drug: CPP‐1X 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐1X 750 mg and sulindac 150 mg
Study: 27480131
Drug: CPP‐1X placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐1X placebo and sulindac 150 mg
Study: 27480131
Drug: CPP‐1X 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP‐1X 750 mg and sulindac placebo
Study: 17198904
Drug: C12 Peptide
Normalized name: C12:0
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C12 Peptide (3.8 g daily for 4 weeks)
Study: 12603176
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg twice daily for 5.5 days
Study: 12603176
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg once daily for 6 days
Study: 12603176
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg twice daily and Simvastatin 40 mg once daily
Study: 9096658
Drug: Etoposide (VP-16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP-16) >4,000 mg/m2
Study: 29185087
Drug: Assistive devices
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistive devices for daily life activities
Study: 27548766
Drug: Enalapril-folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-folic acid (10 mg enalapril and 0.8 mg folic acid daily, n=7545)
Study: 27548766
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg daily, n=7559)
Study: 25335675
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (20 g per day)
Study: 20492851
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) at 10 mg for 1 week and then 20 mg for 1 week
Study: 19057627
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid
Study: 16643445
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (including autologous stem cell transplantation) for patients <60 years
Study: 16643445
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (including autologous stem cell transplantation) for patients aged 60-64 years